GSK is moving an antibody-drug conjugate licensed from Hansoh Pharma into an expanded late-stage development plan after early data signaled potential in gynecological cancers. The company said it will initiate five Phase 3 studies built around the ADC asset as it targets a broader evidence package for regulatory review and payer positioning. In a separate competitive push in the same tumor-adjacent landscape, BioNTech and SynOx are also charting FDA paths on newly published data, with both companies eyeing outcomes in two tumor types. Their moves underscore how quickly ADC and engineered immune modalities are converging in late-stage oncology, where trial execution and registration strategies can shift market share.